GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Bioversys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator ...
BV100 Phase 2 results indicate safety, tolerability, and efficacy in VABP patients with CRAB. Strategic investments from GIBF and GSK support BV100 and alpibectir development, with Phase 3 trials planned for 2025. BV100 targets RNA-polymerase in Gram-negative bacteria, addressing high mortality CRAB infections.
Meningococcal group B vaccine receives Philippine FDA approval
Philippine FDA approved GSK's Meningococcal Group B Vaccine on Oct 15 for individuals aged 2 months or older, addressing a previously unmet need in preventing serogroup B meningococcal disease, which accounts for 68% of IMD cases in the Philippines.
Stock-exchange announcement
PDF file structure and encoding details, including object references and stream data.
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary
FDA accepts GSK's NDA for gepotidacin, a novel oral antibiotic for uUTIs, with a PDUFA action date of 26 March 2025. Gepotidacin, supported by positive EAGLE-2 and EAGLE-3 trials, could be the first new class of oral antibiotic for uUTIs in over 20 years.
GSK's depemokimab shows promise in Phase III trials for chronic rhinosinusitis
GSK announced positive Phase III ANCHOR-1 and ANCHOR-2 trial results for depemokimab in chronic rhinosinusitis with nasal polyps, meeting co-primary endpoints and suggesting significant treatment advancement.
Forbion follows string of startup exits with $2.2B fundraise
Forbion raised 2 billion euros for two new funds, exceeding targets and bringing total AUM to over 5 billion euros. The growth fund focuses on later-stage biotech companies, while the venture fund invests in earlier therapeutics startups. Forbion has 58 active investments and has led or co-led 88% of initial rounds for 26 companies. The firm has seen six investment exits of at least $1 billion in the last 12 months.
Regeneron and Sanofi's Dupixent Tipped to Dominate COPD Biologics Market
Regeneron and Sanofi won FDA approval for Dupixent in COPD, targeting 300,000 U.S. adults with eosinophilic phenotype. GlobalData forecasts $6.57 billion in 2033 sales, while Sanofi and BMO Capital Markets predict $5.5 billion and $2.5 billion respectively. Competitors AstraZeneca, GSK, and Roche have ongoing trials for their biologics in COPD. Regeneron and Sanofi aim to establish market presence before rivals launch.
GSK gets FDA approval for meningococcal vaccine
GSK's Meningococcal Group B Vaccine, first in the Philippines, approved by FDA to prevent invasive meningococcal disease in individuals from two months old. Meningococcal disease is endemic in the Philippines with no seasonal variation, and serogroup B is a leading cause of IMD globally and locally.
Sanofi abandons phase 2 trial of Denali's multiple sclerosis candidate
The K2 trial of oditrasertib, designed to reduce neuronal damage biomarker in MS, failed to meet primary and secondary endpoints. Denali and Sanofi's partnership faced setbacks with other RIPK1 inhibitors, including a phase 2 ALS trial failure. Despite challenges, the MS treatment market is projected to grow significantly.
Antibiotic Resistance Research Report 2024: 6 Key Large Opportunities in this Space and ...
The 'Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type' report outlines market players addressing antimicrobial resistance, including drug manufacturers, biotech companies, and regulatory bodies. It highlights the role of diagnostics in combating AMR and identifies 6 key market opportunities. The report provides five-year market forecasts and profiles over 100 biotech companies.
© Copyright 2025. All Rights Reserved by MedPath